SALT LAKE CITY, March 8 /PRNewswire/ -- MicroConstants, a GLP-compliant Contract Research Organization (CRO) specializing in bioanalytical and pharmacokinetic analysis, has acquired access to a new nanosizing technology that transforms water insoluble compounds into nanoparticles, making formulation preparation and dosing for toxicology studies easier. In multiple cases, our method has been proven to increase the gastro-intestinal absorption of highly insoluble compounds ensuring maximal oral exposure for toxicology studies.
The patented, proprietary nanosizing process used at MicroConstants does not involve water or mechanical shear, so it is faster and more efficient than aqueous-based technologies. Furthermore, the process typically does not require the addition of excipients, leaving the pure Active Pharmaceutical Ingredient (API) ready for easy dispersion as a convenient suspension formulation. Our cost effective technique provides higher dose loading (50-60%), and is amendable to all routes of extravascular administration. The particle size is reproducible and the process is completely scalable.
MicroConstants is a GLP-compliant Contract Research Organization (CRO) dedicated to providing premier quality bioanalytical, drug metabolism, pharmacokinetic, formulation and immunoassay support services to pharmaceutical and biotech companies worldwide. We are the largest bioanalytical LC/MS/MS service provider on the West Coast, and specialize in method development, method validation and sample analysis. For more information about our nanoparticle formulation services, or any of the services offered by MicroConstants, please visit our website at http://www.microconstants.com.
CONTACT: Heather McMahon of MicroConstants, Inc., 1-866-232-9497,
Web site: http://www.microconstants.com/